Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

TheMotleyFool

0 0

AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects.

Source Fool.com

Like: 0

AZN

Share